Top Markets
Coin of the day
Mithra Pharmaceuticals S.A. Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals S.A.

MITRA
Rang in Aktien #30365
Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège,... Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège, Belgium, specializes in the creation, production, and worldwide commercialization of advanced therapeutic solutions. The company's core focus areas include contraception, the management of menopause, and treatments for hormone-dependent cancers. Its robust development pipeline features Estelle, a combined oral contraceptive that has successfully concluded Phase III clinical trials, and Donesta, an estetrol-based oral hormone treatment currently undergoing Phase III development for menopausal symptoms. Mithra's product portfolio also encompasses Myring, a hormonal contraceptive vaginal ring; Tibelia, a therapy designed to address both menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant targeting prostate and breast cancers, as well as various benign gynecological conditions. Furthermore, the company markets NEXTSTELLIS, an established oral contraceptive pill. Their offerings span diverse pharmaceutical formats, including polymeric devices, implants, sterile injectable medications, and hormonal tablets.
Aktienkurs
$0.25620952
Zuletzt synchronisiert: 2024-07-23
Marktkapitalisierung
$17.14M
Veränderung (1 Tag)
10.83%
Veränderung (1 Jahr)
0.00%
Land
BE
Handel Mithra Pharmaceuticals S.A. (MITRA)

Kategorie

P/S-Verhältnis für Mithra Pharmaceuticals S.A. (MITRA)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Mithra Pharmaceuticals S.A. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Mithra Pharmaceuticals S.A. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber